Answers are grounded in this paper and cite their sources.
Rituximab (RTX) is a monoclonal antibody that targets CD20 on B cells and is used to reduce the relapse risk in neuromyelitis optica spectrum disorder (NMOSD). Some patients experience relapse or exacerbation shortly after RTX treatment. We report a 54-year-old female with seronegative NMOSD who relapsed soon after RTX treatment.
No takes yet. Share an insight, caveat, or question.
Yoon‐Ho Hong (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: